- 8/21/2012: Dr. Larson was a finalist for the T1 Catalyst Award from the UCSF Clinical and Translational Science Institute (CTSI), and was featured the news story, Research Offers New Hope for HIV/AIDS Patients with Cancer.
- 8/14/2013: Results of the first-in-man Phase I clinical trial of Hyperpolarized 13C-pyruvate published in Science Translational Medicine
- 10/14/2013: Dr. Larson was featured on the UCSF CTSI LaunchPad talking about his experience with the Catalyst program (and an accompanying UCSF news article)
About the Group
My group is focused on developing novel hyperpolarized carbon-13 metabolic magnetic resonance imaging (MRI) methods, which has clinical potential as a non-invasive tool with applications such as cancer staging and monitoring treatment response. I am also working on development and application of semi-solid tissue MR imaging techniques for positive contrast of tissues such as tendons, bone, and myelin that are invisible with conventional techniques.
Peder Larson, received his PhD in Electrical Engineering under Dwight Nishimura at Stanford University in 2007, and has been at UCSF since then. The group is based in the Byers Hall at the UCSF Mission Bay campus, as a part of the California Institute for Quantitative Biosciences (QB3) at UCSF. The primary facilites available for research include 3T and 7T MRI systems with 3 adjacent Hyperpolarizers, all of which are part of the Surbeck Laboratory for Advanced Imaging, and are supported in part by the NIH-funded Hyperpolarized MRI Technology Resource Center.